Zenas BioPharma, Inc. (ZBIO) Total Return Calculator with Dividends Reinvested

Zenas BioPharma, Inc.

Popular:

The total return for Zenas BioPharma, Inc. (ZBIO) stock is +46.66% over the past 12 months. So far it's down 48.52% this year. The 5-year total return is -1.17%, meaning $10,000 invested in ZBIO stock 5 years ago would be worth $9,883 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in ZBIO 1 year ago, it would be worth $15,689 today — you'd have gained $5,689.

With Dividends Reinvested$15,689+56.89%

Price Only (No DRIP)$15,689+56.89%

Period2025-06-12 → 2026-06-11

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in ZBIO

1Y$14,666+$4,666 (+46.7%)46.7% CAGR

3Y$9,883-$117 (-1.2%)-0.4% CAGR

5Y$9,883-$117 (-1.2%)-0.2% CAGR

10Y$9,883-$117 (-1.2%)-0.1% CAGR

15Y$9,883-$117 (-1.2%)-0.1% CAGR

20Y$9,883-$117 (-1.2%)-0.1% CAGR

30Y$9,883-$117 (-1.2%)-0.0% CAGR

Zenas BioPharma, Inc. did not pay dividends during this period. Total return = price return.

Loading ZBIO total return...

As of 2026-06-12

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-48.52%	—	-48.52%	—	$5,148
1Y	+46.66%	46.66%	+46.66%	—	$14,666
3Y	-1.17%	-0.39%	-1.17%	—	$9,883
5Y	-1.17%	-0.23%	-1.17%	—	$9,883
10Y	-1.17%	-0.12%	-1.17%	—	$9,883
15Y	-1.17%	-0.08%	-1.17%	—	$9,883
20Y	-1.17%	-0.06%	-1.17%	—	$9,883
30Y	-1.17%	-0.04%	-1.17%	—	$9,883

Risk & Highlights

Best Year+303.00%2025

Worst Year-54.42%2024

Max Drawdown-64.79%2025-12-24 → 2026-01-06

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-23.62%	-23.62%	—	+0.41%	-24.0pp
2025	+303.00%	+303.00%	—	+16.64%	+286.4pp
2024	-54.42%	-54.42%	—	+24.00%	-78.4pp

ZBIO outperformed the S&P 500 by 23.97pp over the past year (+46.66% vs +22.68%).

Loading summary...

ZBIO Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
ZBIOZenas BioPharma, Inc.	$793M	-12.9%	-48.5%	+46.7%	—	-1.2%	-1.2%	-1.2%
ARCTArcturus Therapeutics Holdings Inc.	$198M	-19.3%	+11.5%	-44.0%	—	-74.6%	-79.7%	-79.4%
IMVTImmunovant, Inc.	$6.8B	+13.1%	+26.9%	+103.6%	—	+51.6%	+207.0%	+230.5%
ARDXArdelyx, Inc.	$1.4B	-12.4%	-5.9%	+56.5%	—	+45.1%	+213.0%	+166.8%
PRAXPraxis Precision Medicines, Inc.	$7.2B	-25.3%	-13.4%	+456.0%	—	+1628.1%	-17.6%	-40.5%
KYMRKymera Therapeutics, Inc.	$6.8B	-1.4%	+14.0%	+71.4%	—	+230.0%	+64.1%	+149.4%
RCUSArcus Biosciences, Inc.	$2.3B	-6.3%	+0.0%	+156.6%	—	+15.9%	-6.4%	+37.1%
ALKSAlkermes plc	$7.5B	+26.6%	+59.0%	+44.0%	—	+43.9%	+79.5%	+5.8%
HALOHalozyme Therapeutics, Inc.	$8.4B	+6.5%	+0.6%	+31.3%	—	+110.0%	+65.3%	+715.8%
ACADACADIA Pharmaceuticals Inc.	$3.7B	-1.9%	-18.2%	-4.1%	—	-13.1%	-22.0%	-43.9%
INVAInnoviva, Inc.	$1.7B	-0.4%	+12.9%	+5.0%	—	+67.5%	+78.1%	+105.3%

Compare:ZBIO vs ARCT ZBIO vs IMVT ZBIO vs ARDX ZBIO vs ARCT vs IMVT

About ZBIO Dividend Returns

Zenas BioPharma, Inc. (ZBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of ZBIO over the past year?

Zenas BioPharma, Inc. (ZBIO) delivered a return of 46.66% over the past year. Since ZBIO does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in ZBIO be worth today?

A $10,000 investment in Zenas BioPharma, Inc. one year ago would be worth $14,666 today, representing a gain of $4,666.

Q3Does ZBIO pay dividends?

Zenas BioPharma, Inc. (ZBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ZBIO, the total return equals the price-only return.

Q4Did ZBIO beat the S&P 500?

Yes, Zenas BioPharma, Inc. (ZBIO) outperformed the S&P 500 by 23.97 percentage points over the past year. ZBIO delivered a total return of 46.66%, compared to the S&P 500's 22.68%. This 23.97pp alpha means investors in ZBIO earned more than a passive S&P 500 index fund.

Q5What is ZBIO's worst drawdown?

Zenas BioPharma, Inc. (ZBIO) experienced a maximum drawdown of -64.79% over the past year, declining from its peak on 2025-12-24 to its trough on 2026-01-06. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is ZBIO's long-term total return over 10, 20, or 30 years?

Here are Zenas BioPharma, Inc. (ZBIO)'s long-term returns with dividends reinvested. Over 10 years, the total return is -1.2% (-0.1% CAGR) — $10,000 would have grown to $9,883. Over 20 years: -1.2% total return (-0.1% CAGR) — $10,000 → $9,883. Over 30 years: -1.2% total return (-0.0% CAGR) — $10,000 → $9,883. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was ZBIO's best and worst year?

Zenas BioPharma, Inc.'s best calendar year was 2025 with a total return of 303.0%. Its worst year was 2024 with a total return of -54.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 357.4 percentage points.

How much would $100/month in ZBIO be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →